Otello Stampacchia - Net Worth and Insider Trading

Otello Stampacchia Net Worth

The estimated net worth of Otello Stampacchia is at least $178 Million dollars as of 2024-12-27. Otello Stampacchia is the Director, 10% Owner of Morphic Holding Inc and owns about 2,969,582 shares of Morphic Holding Inc (MORF) stock worth over $169 Million. Otello Stampacchia is the CEO, 10% Owner of Omega Alpha SPAC and owns about 501,000 shares of Omega Alpha SPAC (OMEG) stock worth over $5 Million. Otello Stampacchia is also the Director, 10% Owner of Kronos Bio Inc and owns about 3,818,283 shares of Kronos Bio Inc (KRON) stock worth over $4 Million. Details can be seen in Otello Stampacchia's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Otello Stampacchia has not made any transactions after 2021-01-11 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Otello Stampacchia

Otello Stampacchia Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Otello Stampacchia owns 13 companies in total, including Kronos Bio Inc (KRON) , Morphic Holding Inc (MORF) , and Replimune Group Inc (REPL) among others .

Click here to see the complete history of Otello Stampacchia’s form 4 insider trades.

Insider Ownership Summary of Otello Stampacchia

Ticker	Comapny	Transaction Date	Type of Owner
KRON	Kronos Bio Inc	2020-10-14	director & 10 percent owner
MORF	Morphic Holding Inc	2020-12-23	director
REPL	Replimune Group Inc	2018-07-19	director & 10 percent owner
		2019-09-05	director & 10 percent owner
		2019-04-12	10 percent owner
		2018-07-02	10 percent owner
		2018-06-20	10 percent owner
		2014-10-30	10 percent owner
		2021-10-06	10 percent owner
		2021-02-10	10 percent owner
		2021-01-11	director & 10 percent owner & Chief Executive Officer
		2021-03-25	director
		2023-11-02	10 percent owner

Otello Stampacchia Latest Holdings Summary

Otello Stampacchia currently owns a total of 3 stocks. Among these stocks, Otello Stampacchia owns 2,969,582 shares of Morphic Holding Inc (MORF) as of July 1, 2019, with a value of $169 Million and a weighting of 95.18%. Otello Stampacchia owns 501,000 shares of Omega Alpha SPAC (OMEG) as of January 11, 2021, with a value of $5 Million and a weighting of 2.85%. Otello Stampacchia also owns 3,818,283 shares of Kronos Bio Inc (KRON) as of October 14, 2020, with a value of $4 Million and a weighting of 1.98%.

Latest Holdings of Otello Stampacchia

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MORF	Morphic Holding Inc	2019-07-01	2,969,582	56.99	169,236,478
OMEG	Omega Alpha SPAC	2021-01-11	501,000	10.10	5,060,100
KRON	Kronos Bio Inc	2020-10-14	3,818,283	0.92	3,512,820

Holding Weightings of Otello Stampacchia

Otello Stampacchia Form 4 Trading Tracker

According to the SEC Form 4 filings, Otello Stampacchia has made a total of 0 transactions in Morphic Holding Inc (MORF) over the past 5 years. The most-recent trade in Morphic Holding Inc is the acquisition of 133,333 shares on July 1, 2019, which cost Otello Stampacchia around $2 Million.

According to the SEC Form 4 filings, Otello Stampacchia has made a total of 1 transactions in Omega Alpha SPAC (OMEG) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Omega Alpha SPAC is the acquisition of 501,000 shares on January 11, 2021, which cost Otello Stampacchia around $5 Million.

According to the SEC Form 4 filings, Otello Stampacchia has made a total of 1 transactions in Kronos Bio Inc (KRON) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Kronos Bio Inc is the acquisition of 450,000 shares on October 14, 2020, which cost Otello Stampacchia around $9 Million.

Insider Trading History of Otello Stampacchia

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Otello Stampacchia Trading Performance

GuruFocus tracks the stock performance after each of Otello Stampacchia's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Otello Stampacchia is -8.15%. GuruFocus also compares Otello Stampacchia's trading performance to market benchmark return within the same time period. The performance of stocks bought by Otello Stampacchia within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Otello Stampacchia's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Otello Stampacchia

Average Return

Average return per transaction

Outperforming Transactions

1 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-4.31
Relative Return to S&P 500(%)	-6.14

Otello Stampacchia Ownership Network

Ownership Network List of Otello Stampacchia

No Data

Ownership Network Relation of Otello Stampacchia

Otello Stampacchia Owned Company Details

What does Kronos Bio Inc do?

Who are the key executives at Kronos Bio Inc?

Otello Stampacchia is the director & 10 percent owner of Kronos Bio Inc. Other key executives at Kronos Bio Inc include director & 10 percent owner & President & CEO Norbert W Bischofberger , COO & General Counsel Barbara Kosacz , and Chief Scientific Officer Christopher Dinsmore .

Kronos Bio Inc (KRON) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Kronos Bio Inc (KRON). Other recent insider transactions involving Kronos Bio Inc (KRON) include a net purchase of 5,351,696 shares made by Norbert W Bischofberger , a net sale of 40,194 shares made by Jorge Dimartino , and a net sale of 24,032 shares made by Christopher Dinsmore .

In summary, during the past 3 months, insiders sold 0 shares of Kronos Bio Inc (KRON) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 116,028 shares of Kronos Bio Inc (KRON) were sold and 5,351,696 shares were bought by its insiders, resulting in a net purchase of 5,235,668 shares.

Kronos Bio Inc (KRON)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kronos Bio Inc Insider Transactions

No Available Data

What does Morphic Holding Inc do?

Who are the key executives at Morphic Holding Inc?

Otello Stampacchia is the director of Morphic Holding Inc. Other key executives at Morphic Holding Inc include VP Finance and Ops & Secretary Farrell Robert E Jr , General Counsel and Secretary William Devaul , and Chief Scientific Officer Bruce Rogers .

Morphic Holding Inc (MORF) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Morphic Holding Inc (MORF). Other recent insider transactions involving Morphic Holding Inc (MORF) include a net sale of 42,699 shares made by Praveen P. Tipirneni , a net sale of 69,977 shares made by Marc Schegerin , and a net sale of 35,361 shares made by Farrell Robert E Jr .

In summary, during the past 3 months, insiders sold 0 shares of Morphic Holding Inc (MORF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 188,860 shares of Morphic Holding Inc (MORF) were sold and 4,776 shares were bought by its insiders, resulting in a net sale of 184,084 shares.

Morphic Holding Inc (MORF)'s detailed insider trading history can be found in Insider Trading Tracker table.

Morphic Holding Inc Insider Transactions

No Available Data

What does Replimune Group Inc do?

Who are the key executives at Replimune Group Inc?

Otello Stampacchia is the director & 10 percent owner of Replimune Group Inc. Other key executives at Replimune Group Inc include Chief Commercial Officer Sushil Patel , Chief Commercial Officer Christopher Sarchi , and Chief Medical Officer Konstantinos Xynos .

Replimune Group Inc (REPL) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Replimune Group Inc (REPL). Other recent insider transactions involving Replimune Group Inc (REPL) include a net sale of 45,658 shares made by Pamela Esposito , a net sale of 36,807 shares made by Konstantinos Xynos , and a net sale of 12,680 shares made by Christopher Sarchi .

In summary, during the past 3 months, insiders sold 22,453 shares of Replimune Group Inc (REPL) in total and bought 0 shares, with a net sale of 22,453 shares. During the past 18 months, 203,582 shares of Replimune Group Inc (REPL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 203,582 shares.

Replimune Group Inc (REPL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Replimune Group Inc Insider Transactions

No Available Data

What does Gossamer Bio Inc do?

Who are the key executives at Gossamer Bio Inc?

Otello Stampacchia is the director & 10 percent owner of Gossamer Bio Inc. Other key executives at Gossamer Bio Inc include Chief Medical Officer Richard Aranda , director & Executive Chairman Faheem Hasnain , and Chief Financial Officer Bryan Giraudo .

Gossamer Bio Inc (GOSS) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Gossamer Bio Inc (GOSS). Other recent insider transactions involving Gossamer Bio Inc (GOSS) include a net purchase of 293,570 shares made by Bryan Giraudo , a net purchase of 348,828 shares made by Faheem Hasnain , and a net sale of 5,926 shares made by Richard Aranda .

In summary, during the past 3 months, insiders sold 0 shares of Gossamer Bio Inc (GOSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 45,976 shares of Gossamer Bio Inc (GOSS) were sold and 729,000 shares were bought by its insiders, resulting in a net purchase of 683,024 shares.

Gossamer Bio Inc (GOSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gossamer Bio Inc Insider Transactions

No Available Data

What does Immunic Inc do?

Who are the key executives at Immunic Inc?

Otello Stampacchia is the 10 percent owner of Immunic Inc. Other key executives at Immunic Inc include director & CEO & President Daniel Vitt , PAO and Controller Glenn Whaley , and Chief Medical Officer Andreas Muehler .

Immunic Inc (IMUX) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Immunic Inc (IMUX). Other recent insider transactions involving Immunic Inc (IMUX) include a net purchase of 87,300 shares made by Richard Alan Rudick , and a net purchase of 14,000 shares made by Daniel Vitt .

In summary, during the past 3 months, insiders sold 0 shares of Immunic Inc (IMUX) in total and bought 87,300 shares, with a net purchase of 87,300 shares. During the past 18 months, 0 shares of Immunic Inc (IMUX) were sold and 101,300 shares were bought by its insiders, resulting in a net purchase of 101,300 shares.

Immunic Inc (IMUX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immunic Inc Insider Transactions

No Available Data

What does Translate Bio Inc do?

Who are the key executives at Translate Bio Inc?

Otello Stampacchia is the 10 percent owner of Translate Bio Inc. Other key executives at Translate Bio Inc include director & Chief Executive Officer & other: President Renaud Ronald C Jr , Chief Operating Officer & CLO & other: Secretary Paul D. Burgess , and 10 percent owner Shire Human Genetic Therapies, Inc. .

Translate Bio Inc (TBIO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Translate Bio Inc (TBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Translate Bio Inc (TBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Translate Bio Inc (TBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Translate Bio Inc Insider Transactions

No Available Data

What does Kezar Life Sciences Inc do?

Who are the key executives at Kezar Life Sciences Inc?

Otello Stampacchia is the 10 percent owner of Kezar Life Sciences Inc. Other key executives at Kezar Life Sciences Inc include 10 percent owner Morningside Venture Investments Ltd , Chief Business Officer Nicholas Michael Mordwinkin , and 10 percent owner Equal Talent Investments Ltd .

Kezar Life Sciences Inc (KZR) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Kezar Life Sciences Inc (KZR). Other recent insider transactions involving Kezar Life Sciences Inc (KZR) include a net sale of 6,688 shares made by ,

In summary, during the past 3 months, insiders sold 0 shares of Kezar Life Sciences Inc (KZR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 669 shares of Kezar Life Sciences Inc (KZR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 669 shares.

Kezar Life Sciences Inc (KZR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kezar Life Sciences Inc Insider Transactions

No Available Data

What does Paratek Pharmaceuticals Inc do?

Who are the key executives at Paratek Pharmaceuticals Inc?

Otello Stampacchia is the 10 percent owner of Paratek Pharmaceuticals Inc. Other key executives at Paratek Pharmaceuticals Inc include CLO & General Counsel & Sec. William M. Haskel , President & Chief Commercial Adam Woodrow , and Chief Development & Regulatory Randall B. Brenner .

Paratek Pharmaceuticals Inc (PRTK) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Paratek Pharmaceuticals Inc (PRTK). Other recent insider transactions involving Paratek Pharmaceuticals Inc (PRTK) include a net sale of 48,967 shares made by Evan Loh , a net sale of 34,526 shares made by William M. Haskel , and a net sale of 31,250 shares made by Michael Bigham .

In summary, during the past 3 months, insiders sold 0 shares of Paratek Pharmaceuticals Inc (PRTK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 142,346 shares of Paratek Pharmaceuticals Inc (PRTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 142,346 shares.

Paratek Pharmaceuticals Inc (PRTK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Paratek Pharmaceuticals Inc Insider Transactions

No Available Data

What does Theseus Pharmaceuticals Inc do?

Who are the key executives at Theseus Pharmaceuticals Inc?

Otello Stampacchia is the 10 percent owner of Theseus Pharmaceuticals Inc. Other key executives at Theseus Pharmaceuticals Inc include director & 10 percent owner Carl L Gordon , director & 10 percent owner Orbimed Advisors Llc , and 10 percent owner Foresite Capital Fund V, L.p. .

Theseus Pharmaceuticals Inc (THRX) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Theseus Pharmaceuticals Inc (THRX). Other recent insider transactions involving Theseus Pharmaceuticals Inc (THRX) include a net purchase of 700,000 shares made by Foresite Capital Fund V, L.p. , a net purchase of 479,932 shares made by Orbimed Advisors Llc , and a net purchase of 479,932 shares made by Carl L Gordon .

In summary, during the past 3 months, insiders sold 0 shares of Theseus Pharmaceuticals Inc (THRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Theseus Pharmaceuticals Inc (THRX) were sold and 1,659,864 shares were bought by its insiders, resulting in a net purchase of 1,659,864 shares.

Theseus Pharmaceuticals Inc (THRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Theseus Pharmaceuticals Inc Insider Transactions

No Available Data

What does Nuvation Bio Inc do?

Who are the key executives at Nuvation Bio Inc?

Otello Stampacchia is the 10 percent owner of Nuvation Bio Inc. Other key executives at Nuvation Bio Inc include Chief Medical Officer Dongfang Liu , 10 percent owner Omega Fund V Gp, L.p. , and 10 percent owner Omega Fund Iv Gp, L.p. .

Nuvation Bio Inc (NUVB) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Nuvation Bio Inc (NUVB). Other recent insider transactions involving Nuvation Bio Inc (NUVB) include a net purchase of 777,895 shares made by Xiangmin Cui , a net purchase of 5,313,100 shares made by Oleg Nodelman , and a net purchase of 172,189 shares made by Kim D Blickenstaff .

In summary, during the past 3 months, insiders sold 56,361 shares of Nuvation Bio Inc (NUVB) in total and bought 100,000 shares, with a net purchase of 43,639 shares. During the past 18 months, 56,361 shares of Nuvation Bio Inc (NUVB) were sold and 6,363,184 shares were bought by its insiders, resulting in a net purchase of 6,306,823 shares.

Nuvation Bio Inc (NUVB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nuvation Bio Inc Insider Transactions

No Available Data

What does Omega Alpha SPAC do?

Who are the key executives at Omega Alpha SPAC?

Otello Stampacchia is the director & 10 percent owner & Chief Executive Officer of Omega Alpha SPAC. Other key executives at Omega Alpha SPAC include 10 percent owner Alpha Management Omega , Chief Scientific Officer Vincent Ossipow , and 10 percent owner Omega Fund Vi, L.p. .

Omega Alpha SPAC (OMEG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Omega Alpha SPAC (OMEG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Omega Alpha SPAC (OMEG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Omega Alpha SPAC (OMEG)'s detailed insider trading history can be found in Insider Trading Tracker table.

Omega Alpha SPAC Insider Transactions

No Available Data

What does Ikena Oncology Inc do?

Who are the key executives at Ikena Oncology Inc?

Otello Stampacchia is the director of Ikena Oncology Inc. Other key executives at Ikena Oncology Inc include CFO & Head of Corp. Dev. Jotin Marango , Principal Accounting Officer Francisco Oliveira , and Chief Scientific Officer Xiaoyan Michelle Zhang .

Ikena Oncology Inc (IKNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ikena Oncology Inc (IKNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ikena Oncology Inc (IKNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ikena Oncology Inc (IKNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ikena Oncology Inc Insider Transactions

No Available Data

What does Lexeo Therapeutics Inc do?

Who are the key executives at Lexeo Therapeutics Inc?

Otello Stampacchia is the 10 percent owner of Lexeo Therapeutics Inc. Other key executives at Lexeo Therapeutics Inc include director & Chief Executive Officer Richard Nolan Townsend , 10 percent owner Lundbeckfond Invest A/s , and 10 percent owner Omega Fund Vi Gp, L.p. .

Lexeo Therapeutics Inc (LXEO) Insider Trades Summary

Over the past 18 months, Otello Stampacchia made no insider transaction in Lexeo Therapeutics Inc (LXEO). Other recent insider transactions involving Lexeo Therapeutics Inc (LXEO) include a net sale of 85,000 shares made by Richard Nolan Townsend , a net purchase of 454,545 shares made by Longitude Capital Partners Iv, Llc , and a net purchase of 454,545 shares made by Omega Fund Vi Gp, L.p. .

In summary, during the past 3 months, insiders sold 10,000 shares of Lexeo Therapeutics Inc (LXEO) in total and bought 15,000 shares, with a net purchase of 5,000 shares. During the past 18 months, 85,000 shares of Lexeo Therapeutics Inc (LXEO) were sold and 1,151,362 shares were bought by its insiders, resulting in a net purchase of 1,066,362 shares.

Lexeo Therapeutics Inc (LXEO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Lexeo Therapeutics Inc Insider Transactions

No Available Data

Otello Stampacchia Mailing Address

Above is the net worth, insider trading, and ownership report for Otello Stampacchia. You might contact Otello Stampacchia via mailing address: 888 Boylston St., Suite 1111, Boston Ma 02199.

Discussions on Otello Stampacchia

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.